SAS Output

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 861 55% 903 -654 899 -659
ERLYTX 76 351 462% 368 292 403 327
GI 476 109 23% 114 -361 117 -359
GU 450 354 79% 371 -78 363 -87
GYN 57 0 0% 0 -57 0 -57
LEUK 150 120 80% 125 -24 121 -29
LUNG 524 229 44% 240 -283 238 -286
LYMPH 172 26 15% 27 -144 26 -146
MELAN 55 94 171% 98 43 98 43
MMYEL 147 105 71% 110 -36 107 -40
OTHER 0 51   53 53 52 52
SXQOL 0 12   12 12 12 12
Total 3665 2312   2421 -1237 2436 -1229

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 35   36 36 35 35
BREAST 37 312 843% 327 290 314 277
CCD 0 1430   1499 1499 1484 1484
GU 0 0   0 0 0 0
LEUK 69 14 20% 14 -54 14 -55
LUNG 43 603 1402% 632 589 627 584
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 3   3 3 3 3
PREV 0 47   49 49 52 52
SURV 0 115   120 120 116 116
SXQOL 878 4 0% 4 -873 4 -874
Total 1172 2563   2684 1514 2649 1477

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 35   36 36 35 35
BREAST 1595 1173 74% 1230 -364 1213 -382
CCD 0 1430   1499 1499 1484 1484
ERLYTX 76 351 462% 368 292 403 327
GI 476 109 23% 114 -361 117 -359
GU 450 354 79% 371 -78 363 -87
GYN 57 0 0% 0 -57 0 -57
LEUK 219 134 61% 140 -78 135 -84
LUNG 567 832 147% 872 305 865 298
LYMPH 225 26 12% 27 -197 26 -199
MELAN 55 94 171% 98 43 98 43
MMYEL 239 105 44% 110 -128 107 -132
OTHER 0 54   56 56 55 55
PREV 0 47   49 49 52 52
SURV 0 115   120 120 116 116
SXQOL 878 16 2% 16 -861 16 -862
Total 4837 4875   5106 276 5085 248

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 563 56% 590 -421 587 -425
ERLYTX 76 230 303% 241 165 263 187
GI 418 83 20% 87 -330 89 -329
GU 375 227 61% 238 -136 232 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 122 83 68% 87 -34 84 -38
LUNG 441 185 42% 194 -246 190 -251
LYMPH 129 24 19% 25 -103 24 -105
MELAN 55 67 122% 70 15 71 16
MMYEL 85 98 115% 102 17 100 15
OTHER 0 51   53 53 52 52
SXQOL 0 12   12 12 12 12
Total 2770 1623   1699 -1065 1704 -1066

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 35   36 36 35 35
BREAST 10 311 3110% 326 316 313 303
CCD 0 1078   1130 1130 1113 1113
GU 0 0   0 0 0 0
LEUK 69 14 20% 14 -54 14 -55
LUNG 30 424 1413% 444 414 440 410
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 3   3 3 3 3
PREV 0 29   30 30 33 33
SURV 0 74   77 77 75 75
SXQOL 740 4 1% 4 -735 4 -736
Total 994 1972   2064 1072 2030 1036

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 35   36 36 35 35
BREAST 1022 874 86% 916 -105 900 -122
CCD 0 1078   1130 1130 1113 1113
ERLYTX 76 230 303% 241 165 263 187
GI 418 83 20% 87 -330 89 -329
GU 375 227 61% 238 -136 232 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 191 97 51% 101 -89 98 -93
LUNG 471 609 129% 638 167 630 159
LYMPH 182 24 13% 25 -156 24 -158
MELAN 55 67 122% 70 15 71 16
MMYEL 177 98 55% 102 -74 100 -77
OTHER 0 54   56 56 55 55
PREV 0 29   30 30 33 33
SURV 0 74   77 77 75 75
SXQOL 740 16 2% 16 -723 16 -724
Total 3764 3595   3763 6 3734 -30

14-DEC-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

95% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 742 1142% 778 713 774 709
CCD 0 1430   1499 1499 1484 1484
GI 81 45 56% 47 -33 48 -33
GU 215 220 102% 230 15 223 8
LEUK 0 14   14 14 14 14
LUNG 53 25 47% 26 -26 27 -26
LYMPH 7 0 0% 0 -7 0 -7
MELAN 0 6   6 6 6 6
MMYEL 0 89   93 93 91 91
OTHER 0 7   7 7 7 7
PREV 0 47   49 49 52 52
SURV 0 115   120 120 116 116
SXQOL 878 16 2% 16 -861 16 -862
Total 1299 2756   2885 1589 2858 1559

14-DEC-2018 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    A221504 ALLIANCE     1      
    ACCL16N1 SWOG     34      
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   6   1.0  
    S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 29 280 333 6.0 Aug-2019
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 3 0 300 0.0 > 15 Yrs
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.0  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   80   3.5  
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   195   8.2  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   65   3.2  
    B51 Breast, Regional Nodal XRT NRG 22AUG2013:00:00:00   33   1.2  
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   32   1.0  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACRIN 02JAN2014:00:00:00   61   1.7  
    EA1151 Brst, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   256   24.7  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   67   1.8  
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 63 1797 1900 28.8 Mar-2019
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 24 319 1000 18.7 Dec-2021
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   13   0.7  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   156   1.0  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   19   0.8  
    A191402C PROS, Testing Decision Aids for Minority Men ALLIANCE 14JUL2017:00:00:00   17   1.7  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 27 2433 3960 96.0 Mar-2020
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 4 2 1056 0.4 > 15 Yrs
  OTHER EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer ECOG-ACR 17MAY2018:00:00:00   11   1.8  
    S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 31 351 374 15.2 Jan-2019
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 23 544 707 5.0 Aug-2021
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   49   1.0  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   9   0.0  
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   134   3.8  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   15   0.0  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.0  
    EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 ECOG-ACR 01FEB2017:00:00:00   1   0.2  
    EA2165 Anal, Stg II-III, Nivolumab after CMT ECOG-ACR 13APR2018:00:00:00   2   0.3  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   13   1.2  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 14 12 130 1.2 May-2027
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   168   3.0  
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   9   0.8  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   4   0.5  
    S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel SWOG 03DEC2018:00:00:00 0 0 268    
GU II EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) ECOG-ACR 08FEB2018:00:00:00   3   0.5  
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 32 116 180 5.0 Dec-2019
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 22 105 148 9.0 Apr-2019
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   2   0.2  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   4   0.2  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   12   1.8  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACRIN 02FEB2017:00:00:00   20   1.3  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   90   1.8  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 22 199 969 14.8 Mar-2023
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 2 22 1273    
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 56 46 38 1.3 Jul-2018
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  II S1712 CML, chronic phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 4 2 84 0.4 > 15 Yrs
  II-III S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00   78 1670   Temp Close
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   102   2.7  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   19   1.3  
LUNG II EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo ECOG-ACRIN 02MAY2018:00:00:00   18   3.0  
    S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00 14 48 132 4.5 Jun-2020
    S1400K c-Met: ABBV-399 (Process II) SWOG 05FEB2018:00:00:00   28 44   Oct-2018 Temp Close
    S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 4 0 66 0.0 > 15 Yrs
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   45   1.0  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   56   0.0  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   11   0.5  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   78   4.8  
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   640   19.3  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 53 1848   27.8  
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 13 7 28 1.2 May-2020
LYMPH II S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00 16 11 150 1.0 Jun-2030
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   6   0.0  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   14   1.5  
MELAN II S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 52 235 248 2.8 Apr-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 25 18 77 1.3 Aug-2022
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 14 8 64 1.2 Nov-2022
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 16 27 94 2.2 Jun-2021
    S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab SWOG 06DEC2018:00:00:00 0 0 556    
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACRIN 15DEC2015:00:00:00   31   0.7  
MMYEL II S1702 AL Amyloidosis, Relapsed, Isatuximab SWOG 08MAR2018:00:00:00 9 16 39 2.5 Sep-2019
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   247   7.0  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   35   2.7  
  II A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.0  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   10   0.2  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   9   0.2  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   11   0.5  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.2  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.0  
    NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG 12MAY2017:00:00:00   3   0.5  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   5   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   7   0.0  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACRIN 26SEP2016:00:00:00   14   0.5  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 69 223 480 4.3 Nov-2023
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACRIN 30SEP2015:00:00:00   19   1.3  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 14 52 817 6.5 Sep-2028
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACRIN 16AUG2017:00:00:00   17   1.5  
    S1316 Compar. Effectiv. Trial for MBO SWOG 01AUG2014:00:00:00 52 169 200 2.3 Jan-2020
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   21   0.2  
    A221505 Brst, Hypofractionated Post Mast Rad ALLIANCE 01FEB2018:00:00:00   6   1.0  
    NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG 28JUL2017:00:00:00   6   0.3  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

14-DEC-2018 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
    Y ECOG-ACR EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer EAQ162CD Y  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACRIN EAQ152 Communication & education in tumor profiling EAQ152 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
    Y ECOG-ACRIN EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
    Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y ECOG-ACR EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 EA2161 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y ECOG-ACR EA2165 Anal, Stg II-III, Nivolumab after CMT EA2165 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
  GU Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACR EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) EA8153 N  
  LEUK Y SWOG S1712 CML, chronic phase, TKI +/- Ruxolitinib S1712 N  
  LUNG Y SWOG S1400K c-Met: ABBV-399 (Process II) S1400K N Y
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N  
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
    Y ECOG-ACRIN EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo EA5161 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab S1801 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y SWOG S1702 AL Amyloidosis, Relapsed, Isatuximab S1702 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N Y
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG-GY009 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACRIN E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y ECOG-ACRIN EA1151 Brst, Tomosynthesis Mammographic Screening EA1151 N  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
    Y ALLIANCE A191402C PROS, Testing Decision Aids for Minority Men A191402CD Y  
  GI Y SWOG S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel S1815 N  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
  GU Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ECOG-ACRIN EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y ECOG-ACRIN EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACRIN E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221505 Brst, Hypofractionated Post Mast Rad A221505 Y  
    Y NRG NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG-GU003 Y  
    Y   ACCL16N1 ACCL16N1CD    
    Y ALLIANCE A221504 A221504